instrucfions): The goal of this project is to develop and test novel MR metabolic imaging approaches that will help to distinguish recurrent tumor from normal brain'and treatment effects in patients with glioblastoma (GBM). Characterizing temporal changes in tumor size and malignant potential is critically important for making fundamental decisions about patient care. The availability of imaging technologies that can provide more reliable metrics of tumor response to therapy and can identify progression at an early stage is critical for determining when to stop ineffective treatment and for selecting alternative strategies. We will integrate the multi-parametric imaging examination developed and validated in the current cycle of this P01 with novel H- 1 MR spectroscopic imaging techniques and new hyperpolarized C-13 metabolic imaging methods in order to develop improved mertics for evaluating the lesion. Linking in vivo imaging parameters with histological and genomic properties being studied in Project 2 and with information about therapeutic effects from Project 3 will provide important new strategies for selecting and evaluating novel therapeutics.
In Aim 1 we will develop and test a novel 3D H-1 MRSI sequence that provides automated prescription and significantly improved brain coverage for short echo (TE=20-35ms) spectral arrays. This will facilitate the estimation of in vivo levels of myo-lnositol in the same acquisition as choline, creatine and N-acetylasptate.
In Aim 2 we will utilize the unique experience and resources at UCSF to investigate the application of hyperpolarized C-13 MR metabolic imaging to patients with GBM. This exciting new technology has been shown in pre-clinical studies to differentiate tumor from normal tissue and provide a rapid assessment of response to therapy.
In Aim 3 we will use the techniques developed in Aims 1 and 2 in conjunction with image guided tissue sampling in order to determine wheytherthe following metabolic imaging parameters can improve upon the characterization of recurrent tumor and treatment effect: (i) the choline to N-acetylaspartate index, (ii) the ratio of myo-lnositol/choline and (ill) the ratio of hyperpolarized C-13 lactate/pyruvate.

Public Health Relevance

In this Project we will integrate novel metabolic and physiological imaging methods with tissue studies in order to determine which metabolic imaging parameters are the most effective in distinguishing recurrent tumor from treatment effects. This will have a major impact upon the clincial management of patients with GBM and upon the evaluation of novel therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA118816-07
Application #
8738070
Study Section
Special Emphasis Panel (ZCA1-RPRB-2)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
7
Fiscal Year
2014
Total Cost
$592,568
Indirect Cost
$216,984
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Park, Ilwoo; Larson, Peder E Z; Gordon, Jeremy W et al. (2018) Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. Magn Reson Med 80:864-873
Hayes, Josie; Yu, Yao; Jalbert, Llewellyn E et al. (2018) Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol 20:632-641
Mancini, Andrew; Xavier-Magalhães, Ana; Woods, Wendy S et al. (2018) Disruption of the ?1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. Cancer Cell 34:513-528.e8
Vareth, Maryam; Lupo, Janine; Larson, Peder et al. (2018) A comparison of coil combination strategies in 3D multi-channel MRSI reconstruction for patients with brain tumors. NMR Biomed 31:e3929
Li, Yan; Lafontaine, Marisa; Chang, Susan et al. (2018) Comparison between Short and Long Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma. ACS Chem Neurosci 9:130-137
Gordon, Jeremy W; Chen, Hsin-Yu; Autry, Adam et al. (2018) Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. Magn Reson Med :
Choi, Serah; Yu, Yao; Grimmer, Matthew R et al. (2018) Temozolomide-associated hypermutation in gliomas. Neuro Oncol 20:1300-1309
Zhang, Chenan; de Smith, Adam J; Smirnov, Ivan V et al. (2017) Non-additive and epistatic effects of HLA polymorphisms contributing to risk of adult glioma. J Neurooncol 135:237-244
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Anwar, Mekhail; Molinaro, Annette M; Morin, Olivier et al. (2017) Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. Radiat Res 188:303-313

Showing the most recent 10 out of 75 publications